La Merie Publishing

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish reports, offer R&D database access, and provide consulting in pharmacology and biotechnology.

Market Research Report Title Published Pages Price
Antibody Target, Technology & Pipeline Database: 1-Year Subscription Aug 10 2023 40 USD 1,760.00
Claudin 18.2 - Targeted Immunotherapy: A Landscape Analysis of Stakeholders, Drug Modalities, Pipeline and Business Opportunities from an Industry Perspective Aug 8 2023 267 USD 2,365.00
2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics Mar 7 2023 71 USD 528.00
CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing Feb 8 2023 96 USD 2,000.00
RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: Landscape Analysis of Technologies, Targets, Business & Financing Nov 10 2022 418 USD 2,500.00
Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis Jul 6 2022 263 USD 2,000.00
GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis Jul 6 2022 66 USD 670.00
ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis Jun 27 2022 115 USD 1,170.00
Claudin 6: A target opportunity to develop effector-enhanced drug modalities May 30 2022 50 USD 560.00
Cadherin 17: A target opportunity to develop effector-enhanced drug modalities May 30 2022 32 USD 450.00
Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective Jul 1 2021 259 USD 2,550.00
Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective May 11 2020 195 USD 2,350.00
Competitor Analysis: KRAS Inhibitors Oct 16 2019 35 USD 280.00
Competitor Analysis: RORgamma Antagonists and Agonists Oct 16 2019 28 USD 280.00
Competitor Analysis: TGF-beta/Receptor Inhibitors Oct 16 2019 59 USD 306.00
RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective Sep 12 2019 223 USD 2,350.00
Report Package: Bispecific Antibodies Jul 15 2019 584 USD 2,840.00
Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases Jun 25 2019 121 USD 900.00
T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis Jun 11 2019 463 USD 2,700.00
TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals an industry analysis of technologies, stakeholders, deals & trends May 20 2018 294 USD 2,500.00
Competitor Analysis: CDK9 and Mcl-1 Inhibitors Mar 22 2018 26 USD 235.00
Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins Mar 22 2018 53 USD 190.00
Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends Jan 22 2018 252 USD 2,800.00
Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2017 Update Nov 2 2017 58 USD 525.00
mRNA Vaccines & Therapeutics 2017: An Industry Analysis of Technologies, Pipelines, Stakeholders and Deals Jun 22 2017 260 USD 2,520.00
The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities Jan 27 2017 232 USD 2,400.00
Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company Dec 20 2016 288 USD 880.00
Competitor Analysis: CSF-1R Antagonists for Modulation of the Tumor Microenvironment Dec 8 2016 19 USD 220.00
Competitor Analysis: IDO & TDO Inhibitors for Modulation of the Tumor Microenvironment Dec 8 2016 38 USD 220.00
Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β/R, CXCR4, CSF-1R, CD47-SIRPα, Adenosine, STING & Others Dec 8 2016 117 USD 770.00
Report Package: Hot targets for empowered antibody and cell therapy technologies Dec 8 2016 202 USD 1,254.00
Competitor Analysis: CXCR4 Antagonists for Modulation of the Tumor Microenvironment Dec 8 2016 20 USD 220.00
Competitor Analysis: TGF-β Inhibitors for Modulation of the Tumor Microenvironment Dec 8 2016 22 USD 220.00
Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology Dec 8 2016 319 USD 1,386.00
BCMA-Targeted Antibodies & T-Cells in: October 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells: Monthly Tracking Reports Nov 18 2016 27 USD 225.00
Competitor Analysis: Activators of Immune Checkpoints CD40, GITR, OX40, 4-1BB, CD27 & ICOS Nov 18 2016 75 USD 560.00
BCMA-Targeted Immunotherapeutics in: October 2016 R&D and Business Tracker for Bispecific Antibodies Nov 18 2016 21 USD 225.00
CD22: A Suitable Antigen for Targeted Payload Delivery by Immunotherapeutics Nov 18 2016 80 USD 784.00
Anti-CD22 Immunotherapeutics in: October 2016 R&D and Business Tracker for Antibody-Drug Conjugates Nov 18 2016 27 USD 225.00
Competitor Analysis: Inhibitors of Negative Immune Checkpoints CTLA-4, LAG-3, TIM-3 & Others Nov 1 2016 74 USD 550.00
Anti-Her2 Antibody-Drug Conjugates in: September 2016 R&D and Business Tracker for Antibody-Drug Conjugates Oct 26 2016 22 USD 225.00
CD33-Targeted Immunotherapeutics in: September 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells Oct 26 2016 25 USD 225.00
Competitor Analysis: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2016 Oct 26 2016 53 USD 450.00
CD123-Targeted Immunotherapeutics in: September 2016 R&D and Business Tracker for Bispecific Antibodies Oct 26 2016 20 USD 225.00
Competitor Analysis: NGF-TrkA Pathway Agonists & Antagonists 2016 Oct 26 2016 27 USD 225.00
Competitor Analysis Immunotoxins 2016 Sep 1 2016 31 USD 225.00
B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities Aug 1 2016 39 USD 570.00
CD123: a paradigmatic target for immunotherapeutic treatment modalities Aug 1 2016 83 USD 800.00
TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs Jun 7 2016 388 USD 2,750.00
Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases Jun 3 2016 180 USD 560.00

Clients Who Trust Us

Market Research Reports Inc. Customers

Need tailor made market research solution? We can help you with that too.

About Us

At Market Research Reports, Inc. we aim to make it easier for decision makers to find relevant information and locate right market research reports which can save their time and assist in what they do best, i.e. take time-critical decisions.

We work with our associate Global market research firms who are known leaders in their respective domains to obtain right market research solution for our customer’s needs, be it custom research or syndicated research reports.

Contact Us

Market Research Reports, Inc
16192 Coastal Hwy
Lewes
, DE 19958, USA

USA: +1-302-703-9904

India: +91-8762746600

marketresearchreports

info@marketresearchreports.com

User login

Stay Connected